Exostem Biotec Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Methods of generating oligodendrocytes and cell populations comprising same (US 10,385,314) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,783,781 | Methods of generating oligodendrocytes and cell populations comprising same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,385,314 | Methods of generating oligodendrocytes and cell populations comprising same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,752,883 | Generation of neural stem cells and motor neurons In force · From the USPTO record | In force | From the USPTO record | |
| US 10,973,857 | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,053,476 | Generation of cancer stem cells and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,150,963 | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 12,053,493 | Mesenchymal stem cells populations, their products, and use thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 7: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 8 no status recorded